Silver Oak Securities Incorporated Takes $456,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Silver Oak Securities Incorporated acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 6,730 shares of the medical device company's stock, valued at approximately $456,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Norges Bank acquired a new position in DexCom in the 4th quarter valued at $385,367,000. Woodline Partners LP bought a new position in shares of DexCom in the 4th quarter valued at $63,338,000. Northern Trust Corp increased its stake in shares of DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of DexCom in the 4th quarter valued at $41,295,000. Finally, GAMMA Investing LLC increased its stake in shares of DexCom by 5,951.7% in the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock valued at $34,128,000 after purchasing an additional 491,488 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the topic of several recent analyst reports. Wall Street Zen lowered DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Canaccord Genuity Group lifted their price target on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Barclays boosted their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Finally, Citigroup restated a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Trading Up 1.1%

Shares of NASDAQ:DXCM traded up $0.94 during midday trading on Tuesday, reaching $83.88. The company's stock had a trading volume of 1,351,541 shares, compared to its average volume of 4,394,740. The firm has a market capitalization of $32.89 billion, a price-to-earnings ratio of 62.60, a PEG ratio of 1.77 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a 50 day moving average price of $83.49 and a two-hundred day moving average price of $79.87. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 earnings per share. As a group, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In related news, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the sale, the executive vice president directly owned 95,602 shares of the company's stock, valued at approximately $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,190 shares of company stock valued at $2,281,732 in the last 90 days. Corporate insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.